Safety of nateglinide as used in general practice in England: results of a prescription-event monitoring study

Abstract

Nateglinide (Starlix®) is licensed for the treatment of Type 2 diabetes in patients inadequately controlled with metformin. The study objective was to monitor the safety and use of nateglinide prescribed by primary care physicians (GPs) in England, using the observational cohort technique, Prescription–Event Monitoring. Exposure data were derived from… (More)
DOI: 10.1007/s00592-007-0010-y

Topics

1 Figure or Table

Slides referencing similar topics